Redeye provides an initial take following Neem's Hill's Q3 2026 report. Sales came in lower than we expected and were flat compared with Q2 2026 and Q3 2025, which is somewhat surprising given the solid pace of system roll-outs and management's emphasis on rising utilisation. Beyond the topline, the report was relatively undramatic, with continued cost control and a CEO who describes the conditions for Q4 2026 as promising. We will shortly release a research update, in which we expect to make smaller changes to our estimates.
LÄS MER
